메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website

SHANGHAI, Oct. 24, 2025 -- At 15:00 Beijing Time (09:00 am Berlin Time) on October 20, the "Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma BL-B01D1-303 Research Results" was held at the venue of the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin. eChinaHealth held a forum on progress of nasopharyngeal carcinoma, and Biokin Pharma participated in sharing the research results and reported the Iza bren BL-B01D1-303 research report. The Launch Event focused on the BL-B01D1-303 study (hereinafter: 303 Study) led by
- 김갑성 기자
- 2025-10-24 16:40
Gushengtang TCM and 1doc Form Strategic Partnership to Establish Singapore's Integrated TCM Service Model

SINGAPORE, Oct. 24, 2025 -- Gushengtang TCM officially launched its "Master TCM AI" system at GovWare 2025 on October 22. The launch coincides with a strategic partnership with 1doc and a signed agreement with August Global Partners (AGP) for strategic investment, supporting the shift toward evidence-based integrative medicine. Gushengtang's senior leadership, including Founder and Chairman Tu Zhiliang, Group Vice President Zheng Xiang and Vice President Vicky Liem, Chief Technology Officer Hu Zhongkai, and Southeast Asia Vice General Manager Shen Lin, were present at
- 김갑성 기자
- 2025-10-24 15:08
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022

SUZHOU, China, Oct. 24, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I clinical study (Study ID: JSKN022-101) of JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin αvβ6, for the treatment of advanced malignant solid tumors. JSKN022 is the Company's fourth ADC candidate entering clinical development, as well as the world's first PD-L1/αvβ6 bispecific ADC to advance into clinical trials. JSKN022 innovatively
- 김갑성 기자
- 2025-10-24 12:56
HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity

[ 메디채널 김갑성 기자 ] FACO 2025 presentation highlights HCB101's favorable safety, strong receptor occupancy, and confirmed responses in patients with advanced cancers. TAIPEI, SHANGHAI, and SAN FRANCISCO, Oct. 24, 2025 -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies, today presented new results from its ongoing Phase 1 study of HCB101, a novel SIRPα-engineered Fc fusion protein, at the 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025), held October 24-25, 2025, in Shanghai, Mainla
- 김갑성 기자
- 2025-10-24 07:30
World Psoriasis Day 2025: IFPA Calls to Stop the Domino Effect of Psoriasis

IFPA urges recognition of the close link between psoriasis and mental health — and action to prevent its devastating ripple effects. STOCKHOLM, Oct. 24, 2025 -- Every year on October 29, the global community marks World Psoriasis Day, raising awareness and standing in solidarity with more than 60 million people living with psoriatic disease worldwide. This year, IFPA (the International Federation of Psoriasis Associations) launches a global campaign "Stop the Domino Effect". IFPA's "Stop the Domino Effect" is urging policymakers, healthcare pr
- 김갑성 기자
- 2025-10-24 00:13
A New Era in Cervical Cancer Elimination: INNOVAX Presents Global Progress with HPV 9-Valent Vaccine on IPVS 2025 Opening Day

BANGKOK, Thailand, Oct. 23, 2025 -- Xiamen Innovax Biotech Co., Ltd. ("INNOVAX") participated in the 37th International Papillomavirus Society (IPVS) Conference, and hosted a dedicated symposium titled "A New Era of HPV Vaccines: The Efforts from Developing Country Manufacturers for Global Cervical Cancer Elimination" that stimulated significant discussion among attending global experts. Under the theme "Together Against HPV," Innovax also welcomed visitors to Booth #09, engaging with scholars and potential partners. The symp
- 김갑성 기자
- 2025-10-23 23:24
Avaz Joins the PRC-Saltillo Community, Expanding Global AAC Access and Multilingual Innovation

SINGAPORE, Oct. 23, 2025 -- PRC-Saltillo, the parent company of PRC Saltillo Singapore, and a global leader in augmentative and alternative communication (AAC), is proud to announce that Avaz, known for its multilingual, design-forward AAC app, is now a wholly owned subsidiary of PRC-Saltillo. This strategic acquisition marks a significant milestone in PRC-Saltillo's mission to expand access to AAC solutions worldwide. Expanded AAC Portfolio: Avaz's app joins PRC-Saltillo's trusted suite of AAC solutions—including TouchChat®, LAMP Words for Life®, Dialogue® AAC,
- 김장윤(JASON KIM) 기자
- 2025-10-23 23:00
METiS BioTech announces China's First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial

MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) BEIJING, China, Oct. 23, 2025 -- METiS TechBio, a global leader in AI-driven nanodelivery and formulation innovation, today announced that its internally developed small-molecule candidate MTS-004 has successfully met the primary endpoint in its Phase III clinical trial. MTS-004 is China's first drug candidate designed by AI-driven formulation technologies to complete Phase III development, and the first and only therapy for Pseudobulbar Affect (PBA) in the country to reach
- 김갑성 기자
- 2025-10-23 21:21
Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

LEHI, Utah, Oct. 23, 2025 -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes of inflammation-driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational medicine ofirnoflast (HT-6184) for the treatment of Myelodysplastic Syndromes (MDS) — a group of bone marrow disorders characterized by ineffective blood cell production and a risk of progression to acute myeloid leukemia (AML). The FDA grants Orphan Drug Designation to the
- 김갑성 기자
- 2025-10-23 20:15
ArisGlobal Receives Frost & Sullivan's 2025 Global Intelligent MedDRA Coding New Product Innovation Recognition for AI Leadership and Customer Impact

[ 메디채널 김갑성 기자 ] ArisGlobal is honored for its technological breakthrough in intelligent MedDRA coding that enhances accuracy, accelerates compliance workflows, and advances innovation in pharmacovigilance. SAN ANTONIO, Oct. 23, 2025 -- Frost & Sullivan is pleased to announce that ArisGlobal has received the 2025 Global New Product Innovation Recognition in the intelligent MedDRA Coding industry for its outstanding achievements in innovation, customer impact, and market leadership. This recognition highlights ArisGlobal's consistent leadership in developing technology solutions th
- 김갑성 기자
- 2025-10-23 20:05

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-11-03_MON

2025-11-02_SUN

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 03일 07시 00분